Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: LGND stock price vs NTRA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NTRA's multiple
Needs NTRA P/E.
Implied fair value · at LGND's multiple
Needs EPS (TTM) is negative, LGND P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: LGND FY 2025 (ended Dec 31, 2025) · NTRA FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
LIGAND PHARMACEUTICALS INCORPORATED · implied price per share
Bear
$101.45
Base
$119.35
Bull
$137.25
NATERA, INC. · implied price per share
Bear
-$18.59
Base
-$21.87
Bull
-$25.15
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.25x
0.21x
Net debt / EBITDA
Leverage against operating earnings
-2.31x
0.57x
Cash and equivalents
Liquid reserves on the balance sheet
$733.52M
$488.69M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Royalty Pharma plc
LGND vs RPRX
Sarepta Therapeutics, Inc.
LGND vs SRPT
INCYTE CORP
LGND vs INCY
EXELIXIS, INC.
LGND vs EXEL
ILLUMINA, INC.
LGND vs ILMN
EXACT SCIENCES CORP
LGND vs EXAS
AMGEN INC
LGND vs AMGN
VERTEX PHARMACEUTICALS INC / MA
LGND vs VRTX
REGENERON PHARMACEUTICALS, INC.
LGND vs REGN
$252.03M
$363.27M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe LGND can sustain its unusually high margins and 60.4% revenue growth, then holding or accumulating on pullbacks makes sense because the business quality is stronger than NTRA even though the stock still trades above NTRA-implied and DCF value.
LGND's current price of $255.54 is about 30.7% above NTRA-implied price of $177.06, indicating a meaningful valuation premium versus NTRA on the provided P/S framework. However, LGND also trades within its historical band, so the premium is not an obvious outlier relative to its own recent range.
Supporting Metrics
Live quote
Price unavailable
